Sterile Filtration: After purification, the mAb solution is passed through a sterile filter, typically with a pore size of 0.2 microns, to remove any remaining bacteria or other microorganisms.

In recent years, immunotherapeutic development has surged, with the use of immune B cells in hybridoma studies being the most robust method for monoclonal antibody (mAb) discovery. However, hybridoma ...

To secure the antibody, I-Mab is paying $1.8 million upfront to buy Bridge Health, to be followed by noncontingent quarterly ...

Cancer immunotherapy biotech I-Mab, has paused the development of uliledlimab in favour of its now lead candidate givastomig. The Maryland, US-based company saw an uptick in its stock price on 6 ...

A successful mAb-based discovery and development program begins with a comprehensive understanding of cancer cell biological and molecular pathways and how a candidate antibody interrupts these ...

YUMAB’s versatile platform for ultra-fast mAb discovery and efficient lead development makes it a partner of choice for the generation of novel fully human mAbs tailored to the client’s needs ...

SHANGHAI and GAITHERSBURG, Md., Dec. 4, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and ...

Accordingly, we expect the latest development to positively boost the market sentiment toward TECH stock. Bio-Techne has a market capitalization of $8.13 billion.